Singapore markets closed

Straits Times Index
3,297.55
-26.98(-0.81%)
Nikkei
38,814.56
+94.09(+0.24%)
Hang Seng
17,941.78
-170.85(-0.94%)
FTSE 100
8,146.86
-16.81(-0.21%)
Bitcoin USD
66,581.93
+290.77(+0.44%)
CMC Crypto 200
1,379.75
-38.12(-2.69%)

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Add to watchlist

19.72

-0.17

(-0.85%)

At close: 04:00PM EDT

19.62

-0.10

(-0.51%)

After hours:

07:56PM EDT

Trade prices are not sourced from all markets

All

Zacks
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
GlobeNewswire
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
$126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 mill
GlobeNewswire
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per ShareAUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a biotechnology company focused on Alzheimer’s disease, today announced total gross proceeds of over $125 million from cash-exercises of warrants that were previously distributed to its shareholders (the “Warrants”). Gross proceeds from the Warrants represents the issuance of